Oncolytics Biotech Inc. (ONCY)

[Noodle2]

Forbes: "Four Cancer-Killing Viruses To Watch In 2017" (Note: I found the link to this story from Oncorus' website, the previously mentioned privately held company that Celgene helped fund)

Oncolytics gets some air time. I'm sure this story was posted here on this message board last year:

"Reovirus: Canada-based Oncolytics Biotech is in phase 2 trials of its reovirus-based drug, Reolysin, in several tumor types, including breast, prostate and pancreatic cancer. It has also initiated several combination trials of the compound, which is a proprietary version of a virus that in its natural form causes respiratory illnesses. The development path has been plagued with disappointments, though, causing the company’s stock to plummet and ultimately leading to the departure of CEO Brad Thompson.

But the company is pressing on, announcing recently a new trial of Reolysin in combination with Keytruda in pancreatic cancer.

And other research groups have taken an interest in the cough virus and its potential to combat cancer, too. In November, a group of London-based scientists announced that in mouse studies, reovirus seems to kill both liver cancer and hepatitis C, which is the virus that commonly causes liver cancer. They’re now planning trials in people—adding yet another research program to keep an eye on as the oncolytic virus field continues to develop."


https://www.forbes.com/sites/arleneweintraub/2016/12/29/four-cancer-killing-viruses-to-watch-in-2017/#342917bc65cc